Cargando…
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate a...
Autores principales: | Conte, PierFranco, Bisagni, Giancarlo, Piacentini, Federico, Sarti, Samanta, Minichillo, Santino, Anselmi, Elisa, Aieta, Michele, Gebbia, Vittorio, Schirone, Alessio, Musolino, Antonino, Garrone, Ornella, Beano, Alessandra, Rimanti, Anita, Giotta, Francesco, Turletti, Anna, Miglietta, Federica, Dieci, Maria Vittoria, Vicini, Roberto, Balduzzi, Sara, D'Amico, Robert, Guarneri, Valentina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642895/ https://www.ncbi.nlm.nih.gov/pubmed/37748109 http://dx.doi.org/10.1200/JCO.23.00790 |
Ejemplares similares
-
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2019) -
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
por: Dieci, M V, et al.
Publicado: (2019) -
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2023) -
Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2023) -
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2021)